


Amendments to the Claims:



Listing of the Claims:

Claim 1 (original): A pharmaceutical composition for parenteral administration comprising a somatostatin analogue comprising the amino acid sequence of formula I



I

wherein X_1 is a radical of formula (a) or (b)



wherein R_1 is optionally substituted phenyl,

R_2 is $-\text{Z}_1-\text{CH}_2-\text{R}_1$, $-\text{CH}_2-\text{CO}-\text{O}-\text{CH}_2-\text{R}_1$,




wherein Z_1 is O or S, and

X_2 is an α -amino acid having an aromatic residue on the C_α side chain, or an amino acid unit selected from Dab, Dpr, Dpm, His, (Bzl)HyPro, thienyl-Ala, cyclohexyl-Ala and t-butyl-Ala, the residue Lys of said sequence corresponding to the residue Lys⁹ of the native somatostatin-14

in free form, salt form, or protected form and tartaric acid.

Claim 2 (original): A composition according to claim 1 wherein the somatostatin analogue is a compound of formula II



wherein the configuration at C-2 is (R) or (S) or a mixture thereof, and

wherein R is $\text{NR}_1\text{R}_2\text{-C}_{2-6}$ alkylene or guanidine- C_{2-6} alkylene, and each of R_1 and R_2 independently is H or C_{1-4} alkyl,

in free form, salt form or protected form.

Claim 3 (currently amended): A composition according to claim 1 ~~or 2~~ wherein the compound of the somatostatin analogue is in aspartate di-salt form.

Claim 4 (currently amended): A composition according to ~~any preceding claim~~ claim 1 wherein the composition is adjusted to a pH of about 4 to about 4.5.

Claim 5 (original): A composition for parenteral administration buffered at a pH of about 4 to about 4.5 and comprising as active ingredient cyclo[{4-(NH₂-C₂H₄-NH-CO-O-)Pro}-Phg-DTrp-Lys-Tyr(4-Bzl)-Phe] or a pharmaceutically acceptable salt thereof.


Claim 6 (original): A composition according to claim 5 wherein the composition is buffered by an acetate/acetic acid, lactate/ lactic acid, or Glycin / HCl buffer.

Claim 7 (currently amended): Use of a pharmaceutical composition according to ~~any one of claims 1 to 6~~ claim 1 for the preparation of a medicament for acromegaly or cancer.

Claim 8 (original): Use according to claim 6 for the preparation of a medicament for Cushing's Disease.

Claim 9 (currently amended): A method of treating acromegaly or cancer in a subject in need thereof which comprises administering a pharmaceutical composition according to ~~any one of claims 1 to 7~~ claim 1 to the subject.

Claim 10 (original): A compound of formula III



III

wherein R is $\text{NR}_1\text{R}_2\text{-C}_{2-6}\text{alkylene}$ or $\text{guanidine-C}_{2-6}\text{alkylene}$, and each of R_1 and R_2 independently is H or $\text{C}_{1-4}\text{alkyl}$, in free form, in salt form or complex form, or in protected form, e.g. $\text{cyclo}[\{4\text{-(NH}_2\text{-C}_2\text{H}_4\text{-NH-CO-O-)}\text{Pro}\}\text{-DPhg-DTrp-Lys-Tyr(4-Bzl)-Phe}]$.